Oscar Health Keeps 14 Cents of Every Dollar It Collects, and Wall Street Thinks That's Fine

NEW YORK, April 7 —

Oscar Health collected $11.7bn in premium revenue over the last twelve months and kept roughly 14 cents of every dollar after paying medical claims. That 14.4% gross margin is all that stands between Oscar and insolvency. Twice in the last four quarters, it wasn't enough.

What the Street Believes

Wall Street's pitch on Oscar Health: a tech-first insurer hitting its stride, with a slick member experience pulling in enrollees, a proprietary platform sharpening underwriting, and a 9.5x forward P/E that looks like a bargain if the profitability turn holds. Analysts have a $15.40 average target, implying 20.7% upside from today's $12.76. Jim Cramer recently told viewers he'd "start buying it here" and buy more at $9 — framing a potential 30% further decline as a casual dollar-cost-averaging opportunity rather than a reason to question the thesis entirely.

The flaw is in plain sight. The Street is treating Oscar's Q4 earnings beat — $0.92 against a $0.81 estimate — as proof the model works. Q4 is the easiest quarter in health insurance. Members have burned through their deductibles. Elective procedures get pushed into January. Flu season costs haven't fully landed. A Q4 beat tells you almost nothing about whether the business survives the quarters that actually test it.

What the Data Actually Shows

Oscar's earnings over four quarters tell a story the bulls don't want to read. Q1: a 34.7% miss. That's not a rounding error. In most industries, a miss that size gets a CEO hauled before analysts to explain what broke. Q3 missed by 6%. The two beats came in Q2 (8.6%) and Q4 (13.6%) — both quarters where seasonal medical utilization declines or flattens.

This reveals something specific: Oscar's technology platform, the entire reason this company trades at a premium to its profitability, has not solved the oldest problem in health insurance. When deductibles reset in January and members rush to use benefits, Oscar absorbs the cost just like every legacy insurer. When flu season fills urgent care clinics in the fall, Oscar's medical loss ratio spikes just like UnitedHealth's. The difference: UnitedHealth runs at roughly 80-82% medical loss ratios with decades of actuarial data and massive provider network leverage. Oscar is at an estimated 85.6%.

"I Would Start Buying It Here, Buy Some, I'd Buy Half Here, and Then Buy Half at $9 If It Gets There"

Read what Cramer is actually saying. He's telling retail investors to buy a stock while sketching a scenario where it drops another 30%. In what universe is "plan for it to fall to $9" a buy signal? The framing only works if the business model is sound and the price is just noise. The earnings data suggest the opposite: the price action is the signal. The single Q4 beat is the noise.

Here's the number that should keep Oscar bulls awake. At 14.4% gross margin, every single percentage point of unexpected medical cost inflation erases roughly $117mn in gross profit on Oscar's $11.7bn revenue base. That's not theoretical. That's what happens every Q1 when deductible resets hit.

Why This Changes Everything

The bull case rests on the idea that Oscar's technology will gradually push the medical loss ratio lower, widening that 14.4% gross margin toward something a sustainable health insurer needs. Four quarters of data show the opposite. The tech works as a member acquisition engine — Oscar's enrollment growth is real and impressive. But acquiring members cheaply doesn't help if you can't control their medical costs once they're on the plan.

The math: Oscar generated $698mn in free cash flow over the trailing twelve months. That sounds strong until you realize the number is loaded with favorable Q4 and Q2 periods. If Q1 2026 produces another miss anywhere near last year's 34.7%, that trailing FCF figure will look very different by midsummer. At 9.5x forward earnings, the market is pricing in a company that has fixed its cost problem. Two misses in four quarters say it hasn't.

The catalyst is simple. Oscar's next Q1 report will show whether the company has made structural progress on seasonal medical cost swings. A single-digit miss gives the turnaround story a second wind. Another blowout compresses the 9.5x multiple fast — because the market will stop giving Oscar credit for being a "tech company" and start pricing it as the health insurer it is. Health insurers with 85%+ medical loss ratios don't get growth multiples. They get utility multiples.

The Bull Case

The strongest argument for Oscar at $12.76: $698mn in trailing free cash flow on a roughly $5bn market cap gives you a mid-teens FCF yield. If Oscar holds that cash generation even through bad quarters, the stock is genuinely cheap. The ACA exchange market is still growing, and Oscar has captured share in a way legacy insurers haven't matched on the individual market. If Affordable Care Act exchange subsidies get extended or expanded, Oscar's addressable market gets bigger. The enrollment growth that drives revenue keeps compounding.

There's also an argument that the Q1 miss was a one-time event — that Oscar has since repriced plans, tightened network contracts, or improved risk adjustment coding. Those are plausible fixes. But plausible and proven are different things. Until Oscar shows it can survive a Q1 without blowing up its earnings, the "tech-enabled underwriting" story is a marketing pitch, not a financial result. Marketing pitches don't deserve growth multiples.

The Bottom Line

Oscar Health is an $11.7bn revenue business that keeps 14 cents on the dollar and has missed earnings in half its recent quarters, including a 34.7% disaster in the toughest seasonal period. The Street's 20.7% upside target assumes the turnaround is real. The data say the jury is still out. At 9.5x forward earnings, Oscar isn't expensive enough to short, but it's not cheap enough to justify the risk of another Q1 blowup. Wait for the next Q1 report before committing capital. If Oscar keeps its medical loss ratio under control during deductible reset season, the stock is a buy at these levels. If it can't, $9 isn't a buying opportunity. It's a destination. Run the free Oscar Health, Inc. deep-dive →

Basis Report does not hold positions in securities discussed. This is not investment advice.

Frequently Asked Questions

What is Oscar Health's medical loss ratio and why does it matter?

Oscar Health's 14.4% gross margin implies an approximately 85.6% medical loss ratio — about 86 cents of every premium dollar goes to paying medical claims. That leaves almost no room for error. When medical costs spike, as they did in Q1 with a 34.7% earnings miss, there's no buffer to absorb the hit. Large insurers like UnitedHealth typically run lower medical loss ratios, giving them more cushion.

Why did Oscar Health miss Q1 earnings by 34.7%?

Q1 is the most expensive quarter for health insurers because deductibles reset. When the calendar year turns, members' deductibles restart at zero, so the insurer pays a much larger share of medical costs until those deductibles are met. This seasonal pattern is well known, but Oscar's thin gross margin amplifies the damage far more than it does for larger, more diversified insurers.

Is Oscar Health's 9.5x forward P/E ratio cheap?

Compared to high-growth tech companies, yes. But Oscar is a health insurer. The 9.5x multiple assumes sustained profitability improvement. If Oscar keeps missing estimates in bad quarters, the market will likely reprice it closer to the utility-like multiples that mature, thin-margin health insurers receive — which means further downside.

What would change the bearish outlook on Oscar Health?

One thing: a Q1 earnings report without a large miss. If Oscar can show that its technology platform actually dampens seasonal medical cost swings — not just acquires members efficiently — the turnaround story becomes credible and the stock's upside target looks achievable.

How does Oscar Health's $698 million in free cash flow factor into the analysis?

The $698mn trailing twelve-month FCF is real but misleading on its own. It's skewed by favorable Q4 and Q2 periods when medical costs are naturally lower. Another bad Q1 could cut trailing FCF sharply. Watch quarterly cash flow trends rather than the annualized number.